What You Should Know:
– Eko Health, a company specializing in AI-powered cardiac and pulmonary detection, has announced that Dr. Jerome Adams, former U.S. Surgeon General, has joined the company as a Distinguished Medical Advisor.
– Dr. Adams brings with him decades of experience in clinical practice, public health, and policy leadership. His appointment comes at a time of accelerated company growth and a national focus on proactive, community-based early detection of cardiovascular disease.
Dr. Adams Bio/Background
Dr. Jerome Adams is a board-certified anesthesiologist and currently serves as the Executive Director of the Center for Community Health Enhancement and Learning at Purdue University. He is also a Distinguished Professor of Practice in Pharmacy Practice and Public Health at the university. During his time as Surgeon General, Dr. Adams issued significant advisories on key public health issues, including maternal health, hypertension, and the opioid epidemic. These focus areas directly align with Eko’s mission to bring early, AI-powered detection tools to the frontlines of care. As a frequent national media contributor, he is also a vocal advocate for diversity, equity, and inclusion as essential pillars of public health.
Medical Advisor Role and Focus
In his role, Dr. Adams will provide strategic guidance on clinical implementation, product development, and public health partnerships. His experience in government leadership and clinical insight is considered invaluable as Eko aims to expand access to affordable, high-performance cardiac screening in primary care settings. The goal is to make earlier and more accurate detection possible in communities that have not traditionally had access to specialist-level tools. Dr. Adams emphasized that joining Eko is about “closing gaps in care, improving outcomes, and ultimately saving lives” through accessible, AI-powered tools.
With Dr. Adams’s expertise, Eko is deepening its focus on clinical excellence and expanding health equity globally. This includes supporting initiatives like a randomized controlled trial in Nigeria that demonstrated the platform’s ability to improve the detection of peripartum cardiomyopathy.
